Topic starter
06/09/2026 6:20 pm
TL;DR: MCP servers are becoming the control layer between AI agents and life sciences systems, but LEVO argues that uncontrolled agent workflows create exposure across intellectual property, patient data, and regulatory compliance. The governance gap is that legacy IAM, perimeter security, and periodic compliance checks do not match real-time, tool-using AI behaviour.
Editorial analysis by NHI Mgmt Group, based on content published by LEVO: “MCP Security in Life Sciences - Protecting Research and Innovation”.
Key questions
Q: What breaks when AI tools are exposed through loosely governed MCP servers?
A: Loose governance lets model-driven tools cross from context retrieval into state-changing actions without enough oversight.
Q: Why do MCP workflows create regulatory risk for clinical and research systems?
A: Because the agent can move sensitive data across systems in real time, which makes jurisdiction, traceability, and approved-use checks harder to maintain.
Q: What are the warning signs that MCP access is not properly controlled?
A: Warning signs include hard-coded credentials in server files, broad tool permissions, no per-tool ownership, and logs that cannot show which agent made a call.
Practitioner guidance
- Inventory every MCP-connected workflow by data class and regulatory impact Map each agent-to-tool path to the systems it can reach, the data it can touch, and the compliance obligations that apply when it does so.
- Scope agent permissions to the minimum dataset and action set Give each workflow only the specific tools, records, and operations needed for the task, and remove broad access that is convenient but not defensible.
- Enforce inline redaction and residency rules Prevent sensitive trial data, patient information, or proprietary compound data from crossing policy boundaries unless the action is explicitly authorised.
Bottom line: MCP makes AI agents a live governance problem in life sciences because the same workflow can reach research, clinical, and regulatory systems.
Explore further
View Full Forum → | NHI Foundation Course → | Our Services → | Read the full analysis →
06/09/2026 6:21 pm
MCP security in life sciences is really a runtime governance problem. The article is not describing a simple integration risk. It is describing a control-plane shift in which AI agents become intermediaries for research, clinical, and regulatory work, so governance has to move from perimeter policy to action-time decisioning. The practitioner conclusion is that MCP visibility, scoping, and enforcement are now part of the identity control stack.
A few things that frame the scale:
- Half of companies using generative AI will deploy agentic AI by 2027, according to Deloitte's 2025 Technology Predictions.
A question worth separating out:
Q: How should organisations govern AI agents that need database access?
A: Organisations should give AI agents narrow read access by default, separate write privileges from query privileges, and require human approval for any session that can modify data. That keeps agent activity inside a clearly bounded role while preserving auditability and reducing the chance of unsupervised state change.
👉 Read our full editorial: Runtime MCP security for life sciences AI workflows